Joanne Beck
Director/Board Member presso ASTRIA THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/03/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Robert Ford | M | 50 | 9 anni | |
| Jill Milne | M | 56 | 16 anni | |
| Robert Funck | M | 61 | 37 anni | |
| Nicolas Koebel | M | - |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 9 anni |
| Marc Dunoyer | M | 71 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 anni |
| Charles Rowland | M | 65 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 anni |
| Andrea Matthews | F | - | 10 anni | |
| John McCoy | M | 54 | 6 anni | |
| Alicia Secor | F | 62 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 anni |
| Kathryn Collins | F | - | 25 anni | |
| David Elkins | M | 55 | 6 anni | |
| Ken Bate | M | 73 | 10 anni | |
| James Geraghty | M | 70 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 anni |
| Hubert Allen | M | 58 | 18 anni | |
| Simone Song | F | 59 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 7 anni |
| Noah Clauser | M | 51 | 13 anni | |
| Scott House | M | - | 34 anni | |
| Jon Ellis | M | 57 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 anni |
| Paola Gonzalez | F | 52 | 3 anni | |
| Katherine Reynolds Kelly | F | 48 | 5 anni | |
| Philip Boudreau | M | 51 | 27 anni | |
| Claire Babineaux-Fontenot | F | 59 | 2 anni | |
| Darren McDew | M | 63 | 5 anni | |
| Hugh Cole | M | 59 | 5 anni | |
| P. Joseph Campisi | M | - | 5 anni | |
| Bobby Gaspar | M | 60 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 6 anni |
| Frederick Callori | M | 56 | 3 anni | |
| Michelle Kumbier | F | 56 | 6 anni | |
| Scott Leinenweber | M | - | 27 anni | |
| Andrea Spezzi | M | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | 9 anni |
| Daniel Starks | M | 69 | 7 anni | |
| Sally Blount | M | 62 | 13 anni | |
| Michael O'Grady | M | 58 | 1 anni | |
| Melissa Brotz | F | - | - | |
| Rajeev Venkayya | M | - |
Aerium Therapeutics, Inc.
 Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Nancy McKinstry | F | 65 | 13 anni | |
| Michael Roman | M | 64 | 3 anni | |
| Mary Moreland | F | 57 | 13 anni | |
| Robert Alpern | M | 73 | 16 anni | |
| Jonathan Violin | M | 49 | 3 anni | |
| Randel Woodgrift | M | 62 | 12 anni | |
| Michael Kishbauch | M | 75 | 8 anni | |
| Gregg Lapointe | M | 65 | 5 anni | |
| Matt Roden | M | 53 | 5 anni | |
| John Stratton | M | 63 | 7 anni | |
| Michael Powell | M | 69 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Andrew Komjathy | M | 61 | 5 anni | |
| Keri McGrail | F | - | 3 anni | |
| Stephen Knight | M | 63 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Ann Li Lee | M | 63 | 6 anni | |
| Claude Ramoni | M | - |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Takeyoshi Yamashita | M | 62 | - | |
| Christopher J Morabito | M | - | 2 anni | |
| Andrea Wainer | F | - | 27 anni | |
| Jim Leffelman | M | - | - | |
| John Maraganore | M | 60 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| John M. Capek | M | 62 | 18 anni | |
| Gene Huang | M | - | - | |
| Vincent Ossipow | M | 55 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Otello Stampacchia | M | 55 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| Fulvio Mavilio | M | - | 2 anni | |
| Ben Harshbarger | M | 55 | 4 anni | |
| Daniel Gesua Sive Salvadori | M | - | - | |
| Yasuo Fujii | M | - | - | |
| Abdul Mullick | M | - | - | |
| Jeffrey Galik | M | - | 5 anni | |
| Peter Honig | M | 67 |
Aerium Therapeutics, Inc.
Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya. | - |
| John Ruesch | M | - | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Mark Alles | M | 64 | 15 anni | |
| Mark Rothera | M | 62 |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom.
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | 3 anni |
| Jacqualyn Fouse | M | 62 | 7 anni | |
| Deirdre Cunnane | F | 59 | 4 anni | |
| Robert Hugin | M | 69 | 19 anni | |
| Jonathan Biller | M | 61 | 8 anni | |
| Timothy J. Smith | M | - | - | |
| Peter Kellogg | M | 67 | 5 anni | |
| Thomas Daniel | M | 69 | 10 anni | |
| Scott Smith | M | 61 | 10 anni | |
| Jay Backstrom | M | 69 | 11 anni | |
| John Curnutte | M | 72 | 5 anni | |
| Carrie Cox | F | 66 | 10 anni | |
| Rupert Vessey | M | 59 | 4 anni | |
| Thomas Perone | M | 59 | 12 anni | |
| Brendan Delaney | M | 49 | 6 anni | |
| Jacquelyn Sumer | F | 46 | 1 anni | |
| Anne Dupraz-Poiseau | M | - | 6 anni | |
| Michael Friedman | M | 80 | 8 anni | |
| Michael Ross | M | 75 | 9 anni | |
| Jean George | F | 66 | 9 anni | |
| Michael Bonney | M | 65 | 4 anni | |
| Elise T. Wang | F | 64 | - | |
| James J. Loughlin | M | 81 | 12 anni | |
| Richard W. Barker | M | 75 | 7 anni | |
| Burt Adelman | M | 71 | 5 anni | |
| Michael D. Casey | M | 78 | 17 anni | |
| Ernest Mario | M | 85 | 12 anni | |
| Gilla Kaplan | M | 76 | 20 anni | |
| Patricia Hemingway Hall | F | 71 | 1 anni | |
| Robert Hershberg | M | 61 | 5 anni | |
| Craig T. Basson | M | - |
Boston Pharmaceuticals, Inc.
 Boston Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Boston Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that leverages a drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The company was founded by Robert Armstrong and Chris Viehbacher and is headquartered in Cambridge, MA. | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 84 | 84.00% |
| Regno Unito | 17 | 17.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Joanne Beck
- Contatti personali
